Related Experiment Video
Updated: Jul 23, 2025

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
CC Chemokine 2 Promotes Ovarian Cancer Progression through the MEK/ERK/MAP3K19 Signaling Pathway
Wei Liu1, Lei Wang1, Jiajia Zhang1
1College of Life Sciences, Henan Agricultural University, Zhengzhou 450002, China.
Chemokine CCL2 promotes ovarian cancer progression and metastasis by upregulating MAP3K19 via the MEK/ERK pathway. Targeting CCL2 may offer a new therapeutic strategy for ovarian cancer.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Ovarian cancer is a leading cause of gynecological cancer mortality.
- CC chemokine 2 (CCL2) is implicated in various cancers, but its role in ovarian cancer is not fully understood.
Purpose of the Study:
- To investigate the role of CCL2 in ovarian cancer progression.
- To identify the molecular mechanisms by which CCL2 influences ovarian cancer cells.
Main Methods:
- Overexpression and knockdown of CCL2 using CRISPR/Cas9.
- Transcriptome sequencing to identify CCL2 targets.
- MAP3K19 knockout experiments.
- Western blotting to analyze pathway activation (MEK/ERK).
Main Results:
- Exogenous CCL2 and CCL2 overexpression enhanced ovarian cancer cell proliferation and metastasis.
- CCL2 knockdown inhibited ovarian cancer cell proliferation, migration, and invasion.
- MAP3K19 was identified as a key CCL2 target regulating ovarian cancer progression.
- MAP3K19 knockout suppressed ovarian cancer cell proliferation, migration, and invasion.
- CCL2 upregulated MAP3K19 expression via the MEK/ERK pathway.
Conclusions:
- CCL2 promotes ovarian cancer progression and metastasis.
- CCL2 exerts its effects by upregulating MAP3K19 expression through the MEK/ERK pathway.
- CCL2 represents a potential therapeutic target for ovarian cancer treatment.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
MAPK Signaling Cascades
Chemotaxis and Direction of Cell Migration
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Tumor Microenvironment
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

